TEXAS MPJE 2025 STUDY GUIDE |
PHARMACY LAW EXAM PRACTICE
QUESTIONS, ANSWERS & RATIONALES
| GRADED A+ | GUARANTEED SUCCESS
Updated 2026 Questions and Answers
100% Verified Exam Prep and Comprehensive
Rationales Included
,Drug Sample Rules Most pharmacies prohibited from selling, purchasing, trading, or possessing
samples.
EXCEPTIONS: Pharmacies owned by charitable organizations or by a city, state, or
county government and that are part of a healthcare entity providing care to
indigent or low-income patients at no or reduced cost, and must be given at no
charge to patients.
Drug Quality and Security Act of 2013 Addressed large-scale compounding by pharmacies, and establishment of a
framework for a uniform track-and-trace system for prescription drugs throughout
the supply chain.
Drug Compounding Quality Act (DCQA) Maintains traditional compounding regulations but establishes new section to
FDCA that allows facilities that are compounding sterile pharmaceuticals to
register with FDA as outsourcing facility (503B)
These facilities are exempt from new drug provisions, adequate directions for use,
and drug track/trace provisions.
Must:
-RPH overseeing
-Register & report drugs sold every 6 months
-Inspections & pay for them
-Report serious AE w/in 15days
-Label as compounded drug
May not compound meds w/ bulk drug substance, unless:
-They're on list of meds w/ clinical need
-They're on shortage list
Passed in response to fungal meningitis outbreak in 2012 due to contaminated
injectable steroids
503A Pharmacy that compounds pursuant to a prescription.
States with an MOU with the FDA can ship interstate, but not >50% of total scripts.
If no MOU, no more than 5% allowed.
, Drug Supply Chain Security Act (DSCSA) FDA to create and implement national track-and-trace system for
pharmaceuticals.
Transaction data required (maintain for 6 years):
-Transaction Info (includes product identifier)
-Transaction History
-Transaction Statement
Pharmacies can only receive drugs with product identifiers containing 3 elements:
1. Standardized numerical identifier (SNI) which comprises the NDC + unique serial
number
2. Lot number
3. Expiration date
Pharmacy must investigate:
-Suspect products
-Illegitimate products
*Verify the product identifier of 3 products or 10% (whichever is greater)
If illegitimate, notify FDA w/ FDA Form 3911 and trading partners within 24 hours.
Distributing Providing a drug to anyone other than the consumer/patient.
Must have wholesale distribution license and pass DSCSA transaction data.
Exceptions:
-2 entities that are affiliated/under common ownership
-Providing product to another dispenser on a patient specific basis
-Distributing under emergency medical reasons
-Distributing minimal quantities to licensed MD for office use
Adulteration -Filthy, putrid, or decomposed
-Prepared or held under unsanitary conditions and may have been contaminated
-Manufacturing does not conform to cGMP
-Delay, deny, or limit an inspection/refusing to permit entry or inspection
-Container composed of poisonous or deleterious substance that may
contaminate the drug
-Unsafe color additive
-It is in an official compendium, and strength differs from or its quality or purity
falls below compendium standard, unless clearly stated
-Not in a compendium, and strength differs from or quality falls below what is on
the label
-Mixed or packed with any substance that reduces its strength or quality, or has
been substituted in whole or part
If the strength differs from what is represented on the Both
label, is it misbranded or adulterated?
PHARMACY LAW EXAM PRACTICE
QUESTIONS, ANSWERS & RATIONALES
| GRADED A+ | GUARANTEED SUCCESS
Updated 2026 Questions and Answers
100% Verified Exam Prep and Comprehensive
Rationales Included
,Drug Sample Rules Most pharmacies prohibited from selling, purchasing, trading, or possessing
samples.
EXCEPTIONS: Pharmacies owned by charitable organizations or by a city, state, or
county government and that are part of a healthcare entity providing care to
indigent or low-income patients at no or reduced cost, and must be given at no
charge to patients.
Drug Quality and Security Act of 2013 Addressed large-scale compounding by pharmacies, and establishment of a
framework for a uniform track-and-trace system for prescription drugs throughout
the supply chain.
Drug Compounding Quality Act (DCQA) Maintains traditional compounding regulations but establishes new section to
FDCA that allows facilities that are compounding sterile pharmaceuticals to
register with FDA as outsourcing facility (503B)
These facilities are exempt from new drug provisions, adequate directions for use,
and drug track/trace provisions.
Must:
-RPH overseeing
-Register & report drugs sold every 6 months
-Inspections & pay for them
-Report serious AE w/in 15days
-Label as compounded drug
May not compound meds w/ bulk drug substance, unless:
-They're on list of meds w/ clinical need
-They're on shortage list
Passed in response to fungal meningitis outbreak in 2012 due to contaminated
injectable steroids
503A Pharmacy that compounds pursuant to a prescription.
States with an MOU with the FDA can ship interstate, but not >50% of total scripts.
If no MOU, no more than 5% allowed.
, Drug Supply Chain Security Act (DSCSA) FDA to create and implement national track-and-trace system for
pharmaceuticals.
Transaction data required (maintain for 6 years):
-Transaction Info (includes product identifier)
-Transaction History
-Transaction Statement
Pharmacies can only receive drugs with product identifiers containing 3 elements:
1. Standardized numerical identifier (SNI) which comprises the NDC + unique serial
number
2. Lot number
3. Expiration date
Pharmacy must investigate:
-Suspect products
-Illegitimate products
*Verify the product identifier of 3 products or 10% (whichever is greater)
If illegitimate, notify FDA w/ FDA Form 3911 and trading partners within 24 hours.
Distributing Providing a drug to anyone other than the consumer/patient.
Must have wholesale distribution license and pass DSCSA transaction data.
Exceptions:
-2 entities that are affiliated/under common ownership
-Providing product to another dispenser on a patient specific basis
-Distributing under emergency medical reasons
-Distributing minimal quantities to licensed MD for office use
Adulteration -Filthy, putrid, or decomposed
-Prepared or held under unsanitary conditions and may have been contaminated
-Manufacturing does not conform to cGMP
-Delay, deny, or limit an inspection/refusing to permit entry or inspection
-Container composed of poisonous or deleterious substance that may
contaminate the drug
-Unsafe color additive
-It is in an official compendium, and strength differs from or its quality or purity
falls below compendium standard, unless clearly stated
-Not in a compendium, and strength differs from or quality falls below what is on
the label
-Mixed or packed with any substance that reduces its strength or quality, or has
been substituted in whole or part
If the strength differs from what is represented on the Both
label, is it misbranded or adulterated?
